Analyst Upgrades

• Las Vegas Sands (LVS) to outperform from neutral at Credit Suisse.
• Boston Scientific (BSX) to outperform from sector perform at RBC Capital.
• Windstream (WIN) to buy from hold at Citigroup.
• Expeditors (EXPD) to buy from neutral at UBS.
• A123 Systems (AONE) to neutral from underperform and Chesapeake Midstream (CHKM) to buy from neutral at BofA/Merrill.
• AvalonBay (AVB) to outperform from neutral and Post Properties (PPS) to neutral from underperform at Cowen.

Analyst Upgrades

• Verizon (VZ), FEMSA (FMX), Vornado (VNO), Duke Realty (DRE) and AvalonBay (AVB) to buy from neutral, as well as Carnival (CCL) to conviction buy from buy, at Goldman.
• Symantec (SYMC) to buy from hold at Citigroup.
• Copano Energy (CPNO), DCP Midstream (DPM) and Inergy (NRGY) to overweight from equal weight at Morgan Stanley.
• SYNNEX (SNX) to strong buy from buy at Needham.
• Eli Lilly (LLY) to hold from sell at Hapoalim.
• World Wrestling (WWE) to buy from neutral at Roth Capital.

Analyst Upgrades

• Procter & Gamble (PG) upgraded to buy from neutral at Goldman.
• Capital One (COF) upgraded to outperform from market perform at FBR Capital.
• Airgas (ARG) upgraded to outperform from neutral at RW Baird.
• Broadcom (BRCM) upgraded to positive from neutral at Susquehanna.
• Lululemon (LULU) upgraded to hold from underperform at Jefferies.
• DryShips (DRYS) upgraded to outperform from neutral at Credit Suisse.

Analyst Upgrades

• Citigroup assumed coverage of Illinois Tool Works (ITW) and upgraded shares to buy from hold with a $52 price target. Citi cites valuation and the company's successful execution for the rating change.
• UBS upgraded Rowan Companies (RDC) to buy from neutral based on better-than-expected dayrates in the high specification jack-up market. The firm raised its price target to $42 from $28.
• UBS also upgraded NetLogic (NETL) to buy from neutral and keeps a $33.50 target on the stock. The firm upgraded shares based on valuation and solid long-term outlook.
• AvalonBay (AVB) and BRE Properties (BRE) were upgraded to neutral from underperform at Macquarie.
• Covance (CVD) was upgraded to equal weight from underweight at Morgan Stanley.
• Reynolds American (RAI) was upgraded to neutral from underperform at BofA/Merrill.

Analyst Upgrades

• FBR Capital upgraded Pioneer Natural (PXD) to outperform from market perform and raised its price target for shares to $85 from $60. The firm upgraded shares on expectations that returns from the company's Spraberry field will increase materially.
• Baird upgraded Acroda Therapeutics (ACOR) to outperform from neutral based on valuation and a new survey that indicates a strong uptake for Ampyra and improvements on the reimbursement front. The firm has a $40 target on the stock.
• Morgan Stanley upgraded Nokia (NOK) to overweight from underweight based on checks that indicate strong orders and less than expected discounting for its upcoming N8 smartphone.
• GlaxoSmithKline (GSK) and British American Tobacco (BTI) were upgraded to buy from neutral at BofA/Merrill.
• Quality Systems (QSII) was upgraded to outperform from market perform at William Blair.
• Siemens (SI) was upgraded to buy from neutral at UBS.

Analyst Upgrades

• Wunderlich upgraded Inergy (NRGY) to buy from hold on valuation after the stock sold off following the proposed merger with Inergy Holdings (NRGP). The firm raised its target for shares to $46 from $40.
• Soleil upgraded Applied Industrial (AIT) to buy from gradually accumulate following the company's better-than-expected Q4 results and raised its target for shares to $42 from $36.
• Citigroup upgraded Starwood Property (STWD) to buy from hold with a $21 price target, citing a pick-up in CRE loan sales.
• Family Dollar (FDO) was upgraded to overweight from equal weight at Barclays.
• Intercontinental Hotels (IHG) was upgraded to buy from sell at Societe Generale.
• Yucheng Technologies (YTEC) was upgraded to buy from hold at Roth Capital.

Analyst Upgrades

• Auriga upgraded Allscripts (MDRX) to buy from hold to reflect valuation and potential synergies from the company's pending merger with Eclipsys (ECLP). The firm upped its target price for shares to $20 from $19.
• SunTrust upgraded Newell Rubbermaid (NWL) to buy from neutral based on completion of its turnaround plan, stabilizing end markets and favorable comparisons. The firm has a $25 price target on the stock.
• Morgan Joseph upgraded C.R. Bard (BCR) to buy from hold based on valuation and upside to estimates from the share buyback program. The firm has a $97 price target on the stock.
• Shire (SHPGY) was upgraded to buy from hold at Lazard Capital.
• Onyx Pharma (ONXX) was upgraded to outperform from market perform at BMO Capital.
• AvalonBay (AVB) was upgraded to neutral from sell at UBS.

The Street.com's Jim Cramer says that AvalonBay, a builder of luxury apartment complexes, is building more.

If I were to be a short-seller, paying attention to the news flow, I think I would like to be a short-seller of higher-end residential real estate, because I would presume that people couldn't afford it. If they can't make their payments for their houses, they are going to hold out to fix their mortgage or they are going to abandon ship, but they are not going to go to a luxury apartment complex. They are going to go downscale, and the apartment complexes that cater to those who are well-off should be going begging.

I think I would want to short AvalonBay Communities (AVB) (Cramer's Take), which has 172 communities and 50,000 apartments in decimated areas such as Southern California, Northern California, the Midwest and the Pacific Northwest. It must be getting killed. How can it possibly pay those underlying mortgages and how can it grow, building new apartments? It must be a moribund, declining business.

Analyst Upgrades

• FBR Capital upgraded Boston Properties (BXP) and BioMed Realty Trust (BMR) to outperform from market perform after introducing 2011-2012 estimates for the sector. The firm raised its target on Boston Properties to $74.50 from $70 and on BioMed Realty to $17 from $15.50.
• Citigroup upgraded Sysco (SYY) to buy from hold after its channel checks indicated the company's trends are gradually improving. The firm raised its target on shares to $34 from $28.
• Stephens upgraded Smithfield Foods (SFD) to overweight from equal weight on expectations the company's hog production profitability will improve. The firm raised its target price on shares to $20 from $16.
• Nokia (NOK) was upgraded to market perform from underperform at BMO Capital.
• Suntech (STP) was upgraded to market weight from underweight at Thomas Weisel.
• Forest Oil (FST) was upgraded to equal weight from underweight at Morgan Stanley.

Analyst Upgrades

• FBR Capital upgraded Bank of America (BAC) to outperform from market perform to reflect its positive view of the company's $20.5M common equity raise and $45B TARP repayment. The firm believes the $20.5B capital raise is lower than some expected and that Bank of America could potentially announce a new CEO by year-end. FBR raised its price target on shares to $20 from $15.
• JPMorgan upgraded Kennametal (KMT) to overweight from neutral. The firm, which has a $30 target on the stock, cites the recent pullback in shares and believes increased industrial production in 2010 could be a positive catalyst for the company.
• Credit Suisse upgraded Ternium (TX) to outperform from neutral and raised its target to $40 from $31. The firm upgraded shares based on expectations for further improvements in profitability.
• G-III Apparel (GIII) was upgraded to overweight from market weight at Thomas Weisel.
• Cubist Pharma (CBST) was raised to outperform from sector perform at RBC Capital.
• AvalonBay (AVB) was upgraded to neutral from sell at Goldman.

Analyst upgrades:

• Oppenheimer upgraded Momenta Pharmaceuticals (MNTA) to outperform from perform as it finds the stock attractive ahead of FDA's decision on M-enoxaparin. The firm has a $15 price target on the stock.
• Wells Fargo upgraded Symmetry Medical (SMA) to market perform from underperform. The firm cited several factors for the upgrade, including valuation and its belief that Symmetry's customers have begun to deplete their inventories.
• Piper Jaffray upgraded Myriad Pharmaceuticals (MYRX) to neutral from underweight after the company announced Phase 2a date for Azixa. The firm has a $5 price target on shares.
• AvalonBay (AVB) and Mid-America Apartment (MAA) were upgraded to outperform from sector perform at RBC Capital.
• GSI Commerce (GSIC) was upgraded to overweight from equal weight at Morgan Stanley.
• FICO (FICO) was upgraded to equal weight from Underweight at Stephens.

Analyst upgrades:

• Baird upgraded Tenet Healthcare (NYSE: THC) to Outperform from Neutral and raised its target to $6 from $5 based on cost trends, valuation, and expectations the company can beat expectations over the next six months.
• Oppenheimer upgraded E-House (NYSE: EJ) to Outperform from Perform following the company's better-than-expected Q2 results. The firm has a price target of $27 on shares.
• JPMorgan upgraded Avery Dennison (NYSE: AVY) to Overweight from Neutral and has a $33 target on the stock. The firm cites valuation for the upgrade following the recent underperformance and expects the company's margins to expand as demand rebounds.
• Citigroup (NYSE: C) was upgraded to Buy from Underperform at BofA/Merrill.
• Taubman Centers (NYSE: TCO) was upgraded to Conviction Buy from Buy at Goldman.
• First Niagara (NASDAQ: FNFG) was upgraded to Buy from Neutral at Janney Montgomery.

Analyst upgrades:

• Canaccord upgraded Imperial Oil (NYSE: IMO) to Buy from Speculative Buy following an increase in crude oil forecast.
• BT Group (NYSE: BT) was upgraded to Outperform from Market Perform at Bernstein.
  
• Novartis (NYSE: NVS) was upgraded to Overweight from Neutral at JP Morgan.
  
• CommVault (NASDAQ: CVLT) was upgraded to Neutral from Sell at Goldman.
  
• AvalonBay (NYSE: AVB) was upgraded to Buy from Hold at Sandler O'Neill.

"With occupancy rates around 95%, apartment REITs appear to be the one bright spot in the REIT sector," says Asif Suria in The SINLetter; he looks at AvalonBay Communities (NYSE: AVB).

"The company generates nearly half its net operating income from the NY/NJ metro area and New England. California represents an additional 32% of net operating income.

"With a management team that is well respected and leverage that is the lowest of any apartment REIT, AvalonBay has traded at a premium over the last few years and the stock was trading at nearly $150 when I first came across the company in early 2007.

"I continued watching the company over the last two years looking for an opportunity to start a position. With a decline of over 70% from its 2007 high and a yield of 8.1%, this apartment REIT is finally at a level that not only offers a fat yield but also the potential of price appreciation.

Analyst upgrades:

• Jefferies upgraded shares of Devon Energy (NYSE: DVN) to Buy from Hold on expectations that Haynesville results could be a catalyst in 2009. The firm raised their target to $100 from $94.
  
• Friedman Billings upgraded shares of Republic Services (NYSE: RSG) to Outperform from market Perform following the completed merger with Allied Waste (NYSE: AW).
  
• KeyBanc upgraded NorthWestern (NYSE: NWE) to Buy from HOld as they expect the Montana commission to grant the company's pending request for an accounting order to smooth pension expenses over five years.
• EnCana (NYSE: ECA) was upgraded to Neutral from Sell at Goldman.
  
• Goldman also upgraded Questar (NYSE: STR) to Buy from Neutral.
  
• Kinross Gold (NYSE: KGC) was raised to Outperform from Neutral at Credit Suisse.

Analyst downgrades: